AM-Pharma announces 2.5 million EURO financing

AM-Pharma financing kick-starts Series C financing effort

07-Aug-2007

AM-Pharma B.V., a biopharmaceutical company developing improved endogenous proteins to combat disease, announced the signing of a 2.5 million Euro financing agreement with its two main investors, Forbion Capital Partners and Inventages Venture Capital.

The investment is a prelude to a Series C financing round, for which AM-Pharma is now in discussion with potential investors from both Europe and the US. AM-Pharma's main investors aim to participate further in this Series C financing, which will close before the end of this year. Cash raised in the upcoming round will allow the company to generate Phase II efficacy and safety data for two products; recombinant human Alkaline Phosphatase and Anti-Microbial Peptide hLF1-11, in four therapeutic indications; Acute Renal Failure; Ulcerative Colitis; hospital acquired bacterial infections and systemic Candida infection, during the next three years. In this period the value of AM-Pharma is expected to grow significantly.

AM-Pharma recently announced positive results in two Phase IIa studies with Alkaline Phosphatase in Acute Renal Failure and Ulcerative Colitis, whilst Anti-Microbial peptide hLF1-11 showed to be safe in a first trial in bone marrow transplant patients.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances